Expansion● Neutral for Indian equities

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

1 source · first seen 16:30 25 Sept · updated 16:30 25 Sept

The brief

Written from 1 report · check the source before you trade

Analysts say Lilly may have advantages as Novo tries to regain ground in the obesity drug market

Pick a tag to see all its stories

1 report · earliest 16:30